<DOC>
	<DOCNO>NCT01324258</DOCNO>
	<brief_summary>This first clinical experience Japan GSK1120212 , novel MEK inhibitor . This study design identify recommended dos regimens Japanese subject future development GSK1120212 .</brief_summary>
	<brief_title>Trial GSK1120212 GSK1120212 Combination With GEM Japanese Subjects With Solid Tumors</brief_title>
	<detailed_description>GSK1120212 demonstrate anti-proliferative activity broad range tumor cell line xenograft model . To date , MEK inhibitor demonstrate evidence pharmacodynamic clinical activity early trial . This first clinical experience Japan GSK1120212 , novel MEK inhibitor . This study design identify recommended dos regimens Japanese subject future development GSK1120212 . This study conduct subject solid tumor , GSK1120212 single agent treatment ass safety , tolerability , PK efficacy ( Part 1 ) combination treatment gemcitabine subject non-small cell lung cancer , pancreatic cancer , biliary cancer , urothelial cancer tumor type gemcitabine approve 4-week schedule ass safety , tolerability , PK efficacy ( Part 2 ) conduct protocol .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<criteria>Correspond Part 1 ( Single agent ) Part 2 ( Combination ) Capable give write informed consent , include compliance requirement restriction list consent form Age 20 year old old consent give Able swallow retain orally administer medication clinically significant gastrointestinal abnormality may alter absorption malabsorption syndrome major resection stomach bowel Negative hepatitis B surface ( HBs ) antigen , hepatitis virus Bc ( HBc ) antibody , HBs antibody . HBs antigennegative subject test positive HBc antibody HBs antibody either may eligible HBV DNA quantification result negative Negative HCV antibody test Men female partner childbearing potential must either prior vasectomy agree use effective contraception time first dose GSK1120212 16 week last dose GSK1120212 A female subject eligible participate ; Nonchildbearing potential female female subject childbearing potential must agree use contraception four week last dose GSK1120212 sufficiently minimize risk pregnancy point Part 1 Dose escalation single agent part Histologically cytologically confirm diagnosis solid tumor malignancy responsive standard therapy approve curative therapy . Subjects primary brain tumor exclude Adequate organ system function define ; Absolute neutrophil count≥1,200/uL Hemoglobin≥9g/dL Platelets≥75,000/uL PT/INR APTT≤1.3xULN Albumin≥2.5g/dL Total bilirubin≤1.5xULN AST ALT≤2.5xULN Creatinine≤ULN OR Calculated creatinine clearance≥50mL/min OR 24hour urine creatinine clearance≥50mL/min Left ventricular Ejection fraction≥LLN ECHO MUGA Part 2 Combination part Tumor type criterion ; Histologically cytologically confirm diagnosis solid tumor malignancy . Eligible cancer gemcitabine approve 4week schedule ; 1,000mg/m2 weekly 3weeks follow 1 week rest 4th week , include nonsmall cell lung cancer , pancreatic cancer , biliary cancer , urothelial cancer , gemcitabine monotherapy consider appropriate Adequate organ system function define ; Absolute neutrophil count≥1,500/uL Hemoglobin≥9g/dL Platelets≥100,000/uL PT/INR APTT1≤1.3xULN Albumin≥2.5g/dL Total bilirubin≤1.5xULN AST ALT≤2.5xULN Creatinine≤ULN OR Calculated creatinine clearance≥50mL/min OR 24hour urine creatinine clearance≥50mL/min Left ventricular Ejection fraction≥LLN ECHO MUGA Correspond Part 1 ( Single agent ) Part 2 ( Combination ) Any serious and/or unstable preexist medical , psychiatric disorder , condition could interfere subject 's safety , obtain informed consent compliance study procedure Use investigational anticancer drug within 28 day five halflives , whichever short precede first dose GSK1120212 . Or use investigational drug within 28 day five halflives , whichever longer precede first dose GSK1120212 Previous treatment MEK inhibitor History sensitivity study medication , component thereof history drug allergy , opinion investigator subinvestigator , contraindicate participation History interstitial lung disease pneumonitis Current use prohibit medication Any major surgery , radiotherapy , immunotherapy within 21 day initiation GSK1120212 . Or chemotherapy regimen delay toxicity within 21 day initiation GSK1120212 . Or chemotherapy regimen give continuously weekly basis limit potential delayed toxicity within two week initiation GSK1120212 History current evidence/risk retinal vein occlusion ( RVO ) central serous retinopathy ( CSR ) Symptomatic untreated leptomeningeal brain metastasis spinal cord compression QTc B≥480 msec History acute coronary syndrome ( include unstable angina ) , coronary angioplasty , stenting within past 24 week History evidence current≥Class II congestive heart failure define New York Heart Association History evidence current clinically significant uncontrolled arrhythmias History HIV infection Evidence severe uncontrolled systemic disease Unresolved toxicity great CTCAE ( Version 3.0 ) Grade 1 previous anticancer therapy except alopecia Have know immediate delay hypersensitivity reaction idiosyncrasy dimethyl sulfoxide ( DMSO ) Pregnant lactate female Psychological , familial , sociological , geographical condition permit compliance protocol Concurrent condition investigator 's opinion would jeopardize compliance protocol Unwillingness inability follow procedure outline protocol Part 1 Dose escalation single agent part History another malignancy Presence active gastrointestinal disease condition interfere significantly absorption , distribution , metabolism , excretion drug Part 2 Combination part History another malignancy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>pancreatic cancer ( combination gemcitabine )</keyword>
	<keyword>Non-small cell lung cancer ( combination gemcitabine )</keyword>
	<keyword>solid tumor ( single agent )</keyword>
	<keyword>MEK inhibitor</keyword>
	<keyword>GSK1120212</keyword>
	<keyword>biliary cancer ( combination gemcitabine )</keyword>
	<keyword>urothelial cancer ( combination gemcitabine )</keyword>
</DOC>